Nuo Therapeutics (Nuo Therapeutics) Price-to-Operating-Cash-Flow : (As of May. 15, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Nuo Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-05-15), Nuo Therapeutics's share price is $0.75. Nuo Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.08. Hence, Nuo Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Nuo Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

AURX's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 26.61
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Nuo Therapeutics's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.02. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.08.

During the past 13 years, Nuo Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 52.80% per year. The lowest was -32.20% per year. And the median was -2.90% per year.

Nuo Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Nuo Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuo Therapeutics Price-to-Operating-Cash-Flow Chart

Nuo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Nuo Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Nuo Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Nuo Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuo Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Nuo Therapeutics's Price-to-Operating-Cash-Flow falls into.

Nuo Therapeutics Price-to-Operating-Cash-Flow Calculation

Nuo Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	0.75	/	-0.076
	=

Nuo Therapeutics's Share Price of today is $0.75.
Nuo Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.08.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Nuo Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Nuo Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuo Therapeutics (Nuo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuo Therapeutics Inc (OTCPK:AURX) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

8285 El Rio, Suite 190, Houston, TX, USA, 77054

Website

https://www.nuot.com

Nuo Therapeutics Inc is a regenerative therapies company focused on developing and marketing products for chronic wound care primarily within the U.S. Company's commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The company derives revenues from the sale of the Aurix product to customers consisting of primarily hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The Aurix product became commercially available for sale in current financial year.

Executives

Charles E Sheedy	10 percent owner	TWO HOUSTON CENTER, SUITE 2907, HOUSTON TX 77010
David Emerson Jorden	director, officer: CEO, CFO	2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381
Lawrence Atinsky	director	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
C Eric Winzer	director
Paul Mintz	director	C/O NUO THERAPEUTICS INC., 207A PERRY PARKWAY, SUITE 1, GAITHERSBURG MD 20877
Peter Clausen	officer: CSO	11204 JEFFRO COURT, IJAMSVILLE MD 21754
Scott M. Pittman	director	3683 JOHN NASH BLVD., BLUEFIELD WV 24701
Boyalife Investment Fund I, Inc.	10 percent owner	2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Dean Tozer	officer: CHIEF COMMERCIAL OFFICER	C/O ADVANCED BIOHEALING, INC., 36 CHURCH LANE, WESTPORT CT 06880
Steven A Shallcross	officer: SEE REMARKS	C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Aldagen Holdings, Llc	10 percent owner, other: May be part of a 13(d) group	C/O THOMAS A. ALLEN, ESQ., 4101 LAKE BOONE TRAIL, STE 300, RALEIGH NC 27607
Kathryne Carr	10 percent owner, other: May be part of a 13(d) group	315 OLD IVY WAY, SUITE 101, CHARLOTTESVILLE VA 22903
William W Brooke	10 percent owner, other: May be part of a 13(d) group	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Guercio Joseph Del	director	C/O CLARK INVESTMENTS, 7500 OLD GEORGETOWN ROAD, SUITE 620, BETHESDA MD 20814
B. Jefferson Clark	10 percent owner, other: May be part of a 13(d) group	C/O ALDAGEN, INC., 2810 MERDIAN PARKWAY, SUITE 148, DURHAM NC 27713